Homology Medicines Performance
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
The company retains a Market Volatility (i.e., Beta) of 0.71, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Homology Medicines' returns are expected to increase less than the market. However, during the bear market, the loss of holding Homology Medicines is expected to be smaller as well. Homology Medicines right now retains a risk of 0.0%. Please check out Homology Medicines maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Homology Medicines will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Homology Medicines has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Homology Medicines is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 34 M |
Homology |
Homology Medicines Relative Risk vs. Return Landscape
If you would invest 109.00 in Homology Medicines on September 5, 2024 and sell it today you would earn a total of 0.00 from holding Homology Medicines or generate 0.0% return on investment over 90 days. Homology Medicines is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Homology, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Homology Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Homology Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Homology Medicines, and traders can use it to determine the average amount a Homology Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FIXX |
Based on monthly moving average Homology Medicines is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Homology Medicines by adding Homology Medicines to a well-diversified portfolio.
Homology Medicines Fundamentals Growth
Homology Stock prices reflect investors' perceptions of the future prospects and financial health of Homology Medicines, and Homology Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Homology Stock performance.
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (78.85) % | |||
| Current Valuation | (27 M) | |||
| Shares Outstanding | 3.23 M | |||
| Price To Earning | (10.00) X | |||
| Price To Book | 0.04 X | |||
| Price To Sales | 2.61 X | |||
| Revenue | 1.16 M | |||
| EBITDA | (91.52 M) | |||
| Cash And Equivalents | 201.07 M | |||
| Cash Per Share | 3.50 X | |||
| Total Debt | 1.32 M | |||
| Debt To Equity | 0.14 % | |||
| Book Value Per Share | 22.65 X | |||
| Cash Flow From Operations | (96.23 M) | |||
| Earnings Per Share | (35.10) X | |||
| Total Asset | 306.12 M | |||
| Retained Earnings | (542.1 M) | |||
| Current Asset | 48.82 M | |||
| Current Liabilities | 8.27 M | |||
About Homology Medicines Performance
Evaluating Homology Medicines' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Homology Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Homology Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 224 people.Things to note about Homology Medicines performance evaluation
Checking the ongoing alerts about Homology Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Homology Medicines help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Homology Medicines is now traded under the symbol QTTB. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Homology Medicines is not yet fully synchronised with the market data | |
| Homology Medicines has some characteristics of a very speculative penny stock | |
| Homology Medicines has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (112.96 M) with loss before overhead, payroll, taxes, and interest of (95.14 M). | |
| Homology Medicines currently holds about 201.07 M in cash with (96.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Homology Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Homology Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Homology Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Homology Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Homology Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Homology Medicines' stock. These opinions can provide insight into Homology Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |